Syngene International Expands Capabilities
Syngene International, a global contract research, development and manufacturing organization (CRDMO), announces plans to add a GMP bioconjugation suite.
This new capability will enable Syngene to offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing.
The bioconjugation suite will complement commercial payload, linker and monoclonal antibodies services at its commercial biologics facility in Bengaluru.
Syngene will offer fully integrated services for ADCs.
- Location: Bengaluru, India
- Facility: Commercial biologics facility [Unit 3]
- Services: End-to-end services for antibody-drug conjugates (ADCs)
Author's summary: Syngene expands ADC services.